Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: A case-control study

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 2, 2014, Pages 111-115

  Giorda, Carlo B ^a   Picariello, Roberta ^b   Nada, Elisa ^c   Tartaglino, Barbara ^c   Marafetti, Lisa ^a   Costa, Giuseppe ^b,d   Gnavi, Roberto ^b  

^a ASL TO5   (Italy)

^b ASL TO3   (Italy)

^c Chaira Medica Association   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INCRETIN;

ACUTE DISEASE; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; PANCREATITIS; RISK; RISK FACTOR; STATISTICAL MODEL;

ACUTE DISEASE; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; LOGISTIC MODELS; MALE; ODDS RATIO; PANCREATITIS; PATIENT DISCHARGE; RISK FACTORS;

EID: 84894903034     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70147-5     Document Type: Article

References (18)

1. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010, 12:766-771.
2. Noel RA, Braun DK, Patterson RE, Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009, 32:834-838.
3. Blomgren KB, Sundström A, Steineck G, Wiholm BE Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002, 25:298-302.
4. Fimognari FL, Corsonello A, Pastorell R, Antonelli-Incalzi R Metformin-induced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes Care 2006, 29:1183.
5. Mallick S Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J 2004, 80:239-240.
6. Garg R, Chen W, Pendergrass M Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010, 33:2349-2354.
7. Dore DD, Seeger JD, Arnold Chan K Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
8. Dore DD, Blomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011, 13:559-566.
9. Herrera V, Ronald Aubert R, Tully L, et al. Pancreatitis in patients treated with exenatide or sitagliptin [abstract 10-LB]. 69th Scientific Session of the American Association; New Orleans, LA, USA; June 6, 2009.
10. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013, 173:534-539.
11. Moores K, Glichrist B, Carnahan R, Abrams T A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Sat 2012, 21:194-202.
12. Olansky L Q: do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?. Cleve Clin J Med 2010, 77:503-505.
13. Butler PC, Dry S, Elashoff R GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010, 33:453-455.
14. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156.
15. Ostenson CG, Matthaei S, Reaney M, et al. Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes 2013, 6:171-185.
16. Gale EA GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ 2013, 346:f1263.
17. Cohen D Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ 2013, 346:f2607.
18. Lando HM, Alattar M, Dua AP Elevated amylase and lipase levels in patients using glucagon-like peptide-1 receptor agonists or dipeptidyful-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012, 18:472-477.